A detailed history of Vontobel Holding Ltd. transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Vontobel Holding Ltd. holds 43,000 shares of ADAP stock, worth $28,380. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,000
Previous 13,000 230.77%
Holding current value
$28,380
Previous $12,000 233.33%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$0.92 - $1.39 $27,600 - $41,700
30,000 Added 230.77%
43,000 $40,000
Q2 2024

Aug 13, 2024

SELL
$0.83 - $1.47 $8,300 - $14,700
-10,000 Reduced 43.48%
13,000 $12,000
Q1 2024

May 10, 2024

BUY
$0.7 - $1.75 $16,099 - $40,250
23,000 New
23,000 $36,000
Q3 2021

Oct 29, 2021

BUY
$3.44 - $6.37 $10,320 - $19,110
3,000 Added 3.0%
103,000 $533,000
Q1 2021

May 11, 2021

BUY
$4.9 - $6.83 $147,000 - $204,900
30,000 Added 42.86%
100,000 $531,000
Q4 2020

Feb 12, 2021

BUY
$4.0 - $9.2 $280,000 - $644,000
70,000 New
70,000 $377,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $108M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Vontobel Holding Ltd. Portfolio

Follow Vontobel Holding Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Vontobel Holding Ltd. with notifications on news.